



**FTSE
RUSSELL**
An LSEG Business

FTSE Russell Publications

FTSE ETF Connect Innovative Drugs Index

19 August 2026

Indicative Index Weight Data as at Closing on 30 June 2026

Constituent	Index weight (%)	Country/Market	Constituent	Index weight (%)	Country/Market	Constituent	Index weight (%)	Country/Market
3SBio (P Chip)	1.52	CHINA	Exelixis Inc	0.54	USA	PTC Therapeutics	0.55	USA
AbbVie Inc	0.5	USA	Genmab	0.44	DENMARK	Regeneron Phar	0.36	USA
Abivax SA	0.5	FRANCE	Genscript Biotech (P Chip)	1.03	CHINA	RemeGen (H)	3.14	CHINA
Acadia Pharmaceuticals	0.54	USA	Gilead Sciences	0.38	USA	Revolution Medicines	0.86	USA
ADMA Biologics Inc	0.12	USA	Grifols	0.21	SPAIN	Rhythm Pharmaceuticals	1.11	USA
Akeso (P Chip)	3	CHINA	GSK	0.43	UNITED KINGDOM	Roivant Sciences Ltd (A)	1.1	USA
Alkermes plc	0.84	USA	Halozyne Therapeutics	0.27	USA	Royalty Pharma	0.54	USA
Alnylam Pharmaceuticals	0.42	USA	Hansoh Pharmaceutical Group (P Chip)	1.71	CHINA	Sanofi	0.43	FRANCE
Amgen Corp	0.43	USA	HUTCHMED (China)	1.43	HONG KONG	Scholar Rock Holding Corporation	0.6	USA
Argenx S.E	0.58	BELGIUM	Immunovant	0.69	USA	Shanghai Fosun Pharmaceutical Group (H)	0.75	CHINA
Arrowhead Pharmaceuticals Inc.	1.29	USA	Incyte	0.55	USA	Shanghai Junshi Biosciences (H)	3.12	CHINA
Ascentage Pharma Group International (P Chip)	2.74	CHINA	Indivior Pharmaceuticals Inc	0.58	USA	Sichuan Kelun Biotech	4.15	CHINA
AstraZeneca	0.43	UNITED KINGDOM	InnoCare Pharma (P Chip)	3.79	CHINA	Biopharmaceutical (H)		
AXSOME THERAPEUTICS	0.68	USA	Innovent Biologics (P Chip)	1.85	CHINA	Sihuan Pharmaceutical Holdings Group (P Chip)	1.09	CHINA
BeOne Medicines (P Chip)	3.75	CHINA	Insmid Inc	0.68	USA	Sincere Pharmaceutical Group (P Chip)	1.6	CHINA
Biogen	0.52	USA	Ionis Pharmaceuticals	1.01	USA	Sino Biopharm (P Chip)	1.38	CHINA
BioMarin Pharm	0.43	USA	Jazz Pharmaceuticals	0.6	USA	SSY Group (P Chip)	0.79	CHINA
Bio-Techne	0.31	USA	Jiangsu Hengrui Pharmaceuticals (H)	1.7	CHINA	Summit Therapeutics Inc	0.39	USA
BridgeBio Pharma	0.94	USA	Johnson & Johnson	0.46	USA	Takeda Pharmaceutical	0.39	JAPAN
Bristol Myers Squibb	0.43	USA	Keymed Biosciences (P Chip)	5.05	CHINA	Tempus AI	0.51	USA
CanSino Biologics (H)	1.25	CHINA	Krystal Biotech	0.66	USA	Teva Pharmaceutical	0.25	ISRAEL
China Grand Pharmaceutical & Healthcare Holdings (P Chip)	0.62	CHINA	Kymera Therapeutics	1.27	USA	TG Therapeutics Inc	0.86	USA
China Medical System Holdings (P Chip)	0.76	CHINA	Ligand Pharm B	0.69	USA	United Laboratories International Holdings	0.71	HONG KONG
China Resources Pharmaceutical Group (Red Chip)	0.87	CHINA	Lilly (Eli) & Co	0.53	USA	United Therapeutics	0.43	USA
Cogent Biosciences Inc	0.5	USA	Livzon Pharmaceutical Group (H)	0.81	CHINA	Vaxcyte	0.46	USA
Corcept Therapeutics	1.18	USA	Luye Pharma Group (P Chip)	0.7	CHINA	Vertex Pharm	0.46	USA
Crinetics Pharmaceuticals	0.87	USA	Madrigal Pharmaceuticals	0.56	USA	Viartis	0.26	USA
CRISPR Therapeutics	0.98	USA	Merck & Co	0.48	USA	VIKING THERAPEUTICS	0.48	USA
CSPC Pharmaceutical Group (P Chip)	1.5	CHINA	Moderna	1.16	USA	Xenon Pharmaceuticals Inc	0.95	USA
Cytokinetics	1.24	USA	Neurocrine Biosciences	0.58	USA	Zai Lab (P Chip)	3.8	CHINA
Denali Therapeutics	0.55	USA	Novartis (REGD)	0.43	SWITZERLAND			
Duality Biotherapeutics	1.26	HONG KONG	Novo-Nordisk B	0.55	DENMARK			
Everest Medicines (P Chip)	2.55	CHINA	NUVALENT	0.55	USA			
			Pfizer	0.4	USA			
			Praxis Precision Medicines	0.5	USA			
			PROTAGONIST THERAPEUTICS	1.16	USA			

Data Explanation

Weights

Weights data is indicative, as values have been rounded up or down to two decimal points. Where very small values are concerned, which would display as 0.00 using this rounding method, these weights are shown as <0.005.

Timing of data

Constituents & Weights are generally published in arrears and contain the data as at the most recent quarter-end. However, some spreadsheets are updated on a more frequent basis. Please refer to the data date shown.

© 2026 London Stock Exchange Group plc and its applicable group undertakings ("LSEG"). LSEG includes (1) FTSE International Limited ("FTSE"), (2) Frank Russell Company ("Russell"), (3) FTSE Global Debt Capital Markets Inc. and FTSE Global Debt Capital Markets Limited (together, "FTSE Canada"), (4) FTSE Fixed Income Europe Limited ("FTSE FI Europe"), (5) FTSE Fixed Income LLC ("FTSE FI"), (6) FTSE (Beijing) Consulting Limited ("WOFE") (7) Refinitiv Benchmark Services (UK) Limited ("RBSL"), (8) Refinitiv Limited ("RL") and (9) Beyond Ratings S.A.S. ("BR"). All rights reserved.

FTSE Russell® is a trading name of FTSE, Russell, FTSE Canada, FTSE FI, FTSE FI Europe, WOFE, RBSL, RL, and BR. "FTSE®", "Russell®", "FTSE Russell®", "FTSE4Good®", "ICB®", "Refinitiv", "Beyond Ratings®", "WMR™", "FR™" and all other trademarks and service marks used herein (whether registered or unregistered) are trademarks and/or service marks owned or licensed by the applicable member of LSEG or their respective licensors and are owned, or used under licence, by FTSE, Russell, FTSE Canada, FTSE FI, FTSE FI Europe, WOFE, RBSL, RL or BR. FTSE International Limited is authorised and regulated by the Financial Conduct Authority as a benchmark administrator. Refinitiv Benchmark Services (UK) Limited is authorised and regulated by the Financial Conduct Authority as a benchmark administrator.

All information is provided for information purposes only. All information and data contained in this publication is obtained by LSEG, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical inaccuracy as well as other factors, however, such information and data is provided "as is" without warranty of any kind. No member of LSEG nor their respective directors, officers, employees, partners or licensors make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to the accuracy, timeliness, completeness, merchantability of any information or LSEG Products, or of results to be obtained from the use of LSEG products, including but not limited to indices, rates, data and analytics, or the fitness or suitability of the LSEG products for any particular purpose to which they might be put. The user of the information assumes the entire risk of any use it may make or permit to be made of the information.

No responsibility or liability can be accepted by any member of LSEG nor their respective directors, officers, employees, partners or licensors for (a) any loss or damage in whole or in part caused by, resulting from, or relating to any inaccuracy (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analysing, editing, transcribing, transmitting, communicating or delivering any such information or data or from use of this document or links to this document or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if any member of LSEG is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, such information.

No member of LSEG nor their respective directors, officers, employees, partners or licensors provide investment advice and nothing in this document should be taken as constituting financial or investment advice. No member of LSEG nor their respective directors, officers, employees, partners or licensors make any representation regarding the advisability of investing in any asset or whether such investment creates any legal or compliance risks for the investor. A decision to invest in any such asset should not be made in reliance on any information herein. Indices and rates cannot be invested in directly. Inclusion of an asset in an index or rate is not a recommendation to buy, sell or hold that asset nor confirmation that any particular investor may lawfully buy, sell or hold the asset or an index or rate containing the asset. The general information contained in this publication should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional.

Past performance is no guarantee of future results. Charts and graphs are provided for illustrative purposes only. Index and/or rate returns shown may not represent the results of the actual trading of investable assets. Certain returns shown may reflect back-tested performance. All performance presented prior to the index or rate inception date is back-tested performance. Back-tested performance is not actual performance, but is hypothetical. The back-test calculations are based on the same methodology that was in effect when the index or rate was officially launched. However, back-tested data may reflect the application of the index or rate methodology with the benefit of hindsight, and the historic calculations of an index or rate may change from month to month based on revisions to the underlying economic data used in the calculation of the index or rate.

No part of this information may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the applicable member of LSEG. Use and distribution of LSEG data requires a licence from LSEG and/or its licensors.

Data definitions available from lseg.com/ftse-russell

To learn more, visit lseg.com/ftse-russell;
email info@ftserussell.com;
or call your regional Client Services Team office:

Europe, Middle East & Africa

London: + 44 (0) 20 7866 1810

Americas

New York: +1 877 503 6437

Asia Pacific

Hong Kong: + 852 2164 3333

Tokyo: + 81 (3) 6441 1430